Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study
| Autor: | Elisabetta Campagnoli, Marco Alloisio, Emanuela Morenghi, Giorgio Brambilla, Hector Soto Parra, Armando Santoro, F. Latteri, Raffaele Cavina, Walter Torri |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms Neutropenia Time Factors Treatment outcome Deoxycytidine Drug Administration Schedule Injections Dose-Response Relationship Dose-intensity Treatment compliance Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Pharmacology (medical) Non-Small-Cell Lung Lung cancer Aged Pharmacology Cisplatin Dose-Response Relationship Drug business.industry Gemcitabine Non-small-cell lung cancer Female Injections Intravenous Middle Aged Survival Analysis Thrombocytopenia Treatment Outcome medicine.disease Dose intensity Dose–response relationship Drug Intravenous business medicine.drug |
| Zdroj: | Investigational New Drugs. 25:57-62 |
| ISSN: | 1573-0646 0167-6997 |
| Popis: | Three and 4-week cisplatin-gemcitabine schedules have shown similar dose-intensity (DI) and activity in non-small-cell lung cancer (NSCLC). The 3-week schedule is generally preferred because it enables better treatment compliance. To improve DI and compliance further, we delivered gemcitabine plus cisplatin over 4 days every 21 days.Patients with any stage NSCLC or epithelial neoplasms and an ECOG PSor = 2 were given gemcitabine 1000 mg/m(2) on days 1 and 4 plus cisplatin 70 mg/m(2) on day 2 of a 21-day cycle. Minimax design was used and a received DI for gemcitabine ofor = 580 mg/m(2)/wk was considered successful.Thirty-nine patients (34 NSCLC, 5 epithelial neoplasias) were enrolled. SWOG grade 3-4 neutropenia and thrombocytopenia were observed in 17.9% and 12.8% of patients, respectively. Nonhematological toxicity was minimal. Twenty-eight (18%) of 158 cycles required dose modifications and/or delays. Twenty-five patients received a gemcitabine dose intensity ofor = 580 mg/m(2)/wk. The received DIs were 601.8 mg/m(2)/wk for gemcitabine and 21.0 for cisplatin, with a relative DIs of 90.3% and 90.1%, respectively. The response rate of 27 evaluable patients with NSCLC was 44% (95% confidence interval [CI], 25.3 to 62.7%).The shorter schedule of gemcitabine on days 1 and 4 plus cisplatin on day 2 produces an effective DI and a toxicity profile comparable to that of weekly regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink